Alnylam Pharmaceuticals' Income towards Parent Company rose 325.05% to $251.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year increase of 113.11%. This contributed to the annual value of -$278.2 million for FY2024, which is 36.82% up from last year.
According to the latest figures from FY2024, Alnylam Pharmaceuticals' Income towards Parent Company is -$278.2 million, which was up 36.82% from -$440.2 million recorded in FY2023.
Over the past 5 years, Alnylam Pharmaceuticals' Income towards Parent Company peaked at -$278.2 million during FY2024, and registered a low of -$1.1 billion during FY2022.
For the 3-year period, Alnylam Pharmaceuticals' Income towards Parent Company averaged around -$616.5 million, with its median value being -$440.2 million (2023).
Its Income towards Parent Company has fluctuated over the past 5 years, first slumped by 32.64% in 2022, then surged by 61.08% in 2023.
Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Income towards Parent Company stood at -$858.3 million in 2020, then increased by 0.64% to -$852.8 million in 2021, then crashed by 32.64% to -$1.1 billion in 2022, then soared by 61.08% to -$440.2 million in 2023, then skyrocketed by 36.82% to -$278.2 million in 2024.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value